Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Population Pharmacokinetics of the Antituberculosis Agent Pretomanid.

Salinger DH, Subramoney V, Everitt D, Nedelman JR.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e00907-19. doi: 10.1128/AAC.00907-19. Print 2019 Oct.


Pharmacokinetics and Safety of Valganciclovir in Pediatric Heart Transplant Recipients 4 Months of Age and Younger.

Bradley D, Moreira S, Subramoney V, Chin C, Ives J, Wang K; Valcyte NP22523 Study Team.

Pediatr Infect Dis J. 2016 Dec;35(12):1324-1328.


Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment.

Kamal MA, Brennan BJ, Subramoney V, Lien YT, Morcos PN, Frey N, Rayner CR.

Clin Pharmacol Drug Dev. 2015 Sep;4(5):326-36. doi: 10.1002/cpdd.203. Epub 2015 Jul 2.


Investigating clinically adequate concentrations of oseltamivir carboxylate in end-stage renal disease patients undergoing hemodialysis using a population pharmacokinetic approach.

Kamal MA, Lien KY, Robson R, Subramoney V, Clinch B, Rayner CR, Gibiansky L.

Antimicrob Agents Chemother. 2015 Nov;59(11):6774-81. doi: 10.1128/AAC.01024-15. Epub 2015 Aug 17.


Population pharmacokinetic analysis of oseltamivir and oseltamivir carboxylate following intravenous and oral administration to patients with and without renal impairment.

Gibiansky L, Giraudon M, Rayner CR, Brennan BJ, Subramoney V, Robson R, Kamal MA.

J Pharmacokinet Pharmacodyn. 2015 Jun;42(3):225-36. doi: 10.1007/s10928-015-9411-7. Epub 2015 Mar 29.


Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.

Kamal MA, Van Wart SA, Rayner CR, Subramoney V, Reynolds DK, Bulik CC, Smith PF, Bhavnani SM, Ambrose PG, Forrest A.

Antimicrob Agents Chemother. 2013 Aug;57(8):3470-7. doi: 10.1128/AAC.02438-12. Epub 2013 May 13.

Supplemental Content

Loading ...
Support Center